Validation of ERCC1/2 signature as radiosensitivity biomarker for tumor & normal tissues in NSCLC

A genetic analysis of non-small cell lung cancer (NSCLC) patients on the phase III NRG Oncology RTOG 0617 clinical trial assessing radiation dose discovered that high dose radiation therapy is associated with shorter survival times among patients with a radiation-sensitive genotype in DNA repair pathway. These findings were presented at the virtual edition of the American Society for Radiation Oncology’s (ASTRO) Annual Meeting in October 2020.